Short Interest in Invivyd, Inc. (NASDAQ:IVVD) Rises By 28.5%

Invivyd, Inc. (NASDAQ:IVVD) was the target of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 8,510,000 shares, a growth of 28.5% from the January 31st total of 6,620,000 shares. Approximately 11.2% of the shares of the company are sold short. Based on an average daily volume of 13,950,000 shares, the short-interest ratio is currently 0.6 days.

Invivyd Trading Down 4.2 %

Shares of NASDAQ:IVVD traded down $0.05 during trading on Thursday, reaching $1.02. The stock had a trading volume of 638,801 shares, compared to its average volume of 21,009,426. Invivyd has a one year low of $0.35 and a one year high of $4.74. The firm’s 50-day simple moving average is $0.90 and its 200 day simple moving average is $0.87. The company has a market capitalization of $121.41 million, a P/E ratio of -0.52 and a beta of 0.61.

Insider Buying and Selling at Invivyd

In other news, Director Terrance Mcguire sold 160,400 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $0.59, for a total value of $94,636.00. Following the completion of the sale, the director now directly owns 4,202,679 shares of the company’s stock, valued at $2,479,580.61. This represents a 3.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders sold 816,466 shares of company stock valued at $423,214. Company insiders own 17.90% of the company’s stock.

Institutional Trading of Invivyd

A number of institutional investors have recently bought and sold shares of IVVD. Barclays PLC raised its holdings in shares of Invivyd by 7.8% in the fourth quarter. Barclays PLC now owns 127,180 shares of the company’s stock worth $56,000 after buying an additional 9,207 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in shares of Invivyd in the 3rd quarter valued at $27,000. State Street Corp raised its stake in Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after acquiring an additional 35,904 shares during the last quarter. Jane Street Group LLC lifted its position in Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock worth $52,000 after acquiring an additional 87,358 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in Invivyd during the 4th quarter valued at about $74,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IVVD has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a research report on Monday, February 24th. Morgan Stanley reduced their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Finally, D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of Invivyd in a report on Wednesday. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Invivyd currently has a consensus rating of “Buy” and a consensus target price of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.